Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03501940 No longer available - Clinical trials for Prostate Adenocarcinoma

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

NCT ID: NCT03005262 No longer available - Prostate Cancer Clinical Trials

MLN8237 for a Subject With Adenocarcinoma of the Prostate

Start date: n/a
Phase:
Study type: Expanded Access

To allow a patient continued access to MLN8237

NCT ID: NCT02307812 No longer available - Gastric Cancer Clinical Trials

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.

NCT ID: NCT02065765 No longer available - Clinical trials for Metastatic Gastric Cancer

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.

NCT ID: NCT00636259 No longer available - Clinical trials for Adenocarcinoma of the Prostate

Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.